scholarly journals Treatment of mixed anxiety and depressive disorder: results from a observational study of the efficacy and tolerability of agomelatine

2021 ◽  
Vol 13 (6) ◽  
pp. 48-54
Author(s):  
D. S. Petelin ◽  
I. V. Niinoya ◽  
O. V. Sorokina ◽  
D. V. Troshina ◽  
O. N. Voskresenskaya ◽  
...  
Keyword(s):  
Depressive Disorder ◽  
Short Form ◽  
Depression Scale ◽  
Life Questionnaire ◽  
Hamilton Depression Scale ◽  
Depression And Anxiety ◽  
Workplace Performance ◽  
Symptoms Of Depression ◽  
Hamilton Anxiety Scale

Objective: to study the efficacy, safety and tolerability of agomelatine in mixed anxiety and depressive disorder.Patients and methods. Agomelatine was administered to 30 patients diagnosed with mixed anxiety and depressive disorder for 3 months. The patients' condition was assessed using a battery of psychometric methods – the Hamilton Depression Scale, the Hamilton Anxiety Scale, and a short form of the SF-12v2 quality of life questionnaire.Results and discussion. It was shown that agomelatine effectively reduces both symptoms of depression and anxiety, begins to have a therapeutic effect a week after the start of administration, however, the drug shows the best clinical effect when administered for a period of three months or more. The predictors of complete remission on agomelatine therapy in this sample were: the presence of sleep disorders (early and medium, but not late insomnia), a greater severity of somatized anxiety, the presence of complaints of decreased workplace performance and activity.Conclusion. Our study has shown that agomelatine is an effective, safe and well-tolerated drug in the treatment of mixed anxiety and depressive disorder.

scholarly journals Quality of life, anxiety and depressive disorders in patients with extrasystolic arrhythmia

2020 ◽  
Author(s):  
Alexey Y. Mikhaylov ◽  
Alexei V. Yumashev ◽  
Eugeny Kolpak
Keyword(s):  
Depressive Disorder ◽  
Depressive Disorders ◽  
Depression Scale ◽  
Depression And Anxiety ◽  
Ventricular Extrasystole ◽  
Significant Difference ◽  
Different Types ◽  
Development Of Anxiety ◽  
Assessment Scales

IntroductionThe aim of this study was to perform a comparative and economic analysis of the degree of development of anxiety-depressive disorder in patients with different types of extrasystolic arrhythmia using different assessment scales.Material and methodsThe study was conducted in 2018–2019 at the premises of clinic No. 4, involving 450 patients (Moscow, Russia). Patients were divided into three groups: with coronary heart disease (CHD) (147 patients), with myocardiodystrophy (MCD) (113) and with cardiopsychoneurosis (CPN) (190). Everyone underwent round-the-clock electrocardiography (ECG) and echocardiography. If symptoms of depressive disorder are detected in a timely manner, the risk of adverse cardiovascular diseases may be reduced.ResultsDepression and anxiety indicators on all three scales differed significantly (p ≤ 0.05) in patients with supraventricular extrasystole (more than 40 points on the Zung scale, 14 points on the Montgomery-Asberg depression scale, more than 38 points on Zung and 3 points on Covi anxiety scales). For patients with ventricular extrasystole, a significant difference was established between groups 1 and 2 only in terms of the level of depression on the Zung scale. Factors of psychogenic origin determine the development of cardiac rhythm disturbances.ConclusionsThe study showed that for supraventricular extrasystoles, these factors determine the overall health of the patient. The differences between the three groups are significant on all scales of depression and anxiety (p ≤ 0.05). The most susceptible to depression and anxiety are patients with extrasystolic arrhythmias diagnosed with CHD, as well as MCD.

Obesity and quality of life in bipolar disorder

2017 ◽  
Vol 41 (S1) ◽  
pp. S423-S424
Author(s):  
R. Jouini ◽  
H. Ben Ammar ◽  
G. Hamdi ◽  
N. Smari ◽  
A. Aissa ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Bipolar Disorder ◽  
Scale Score ◽  
Rating Scale ◽  
Short Form ◽  
Depression Scale ◽  
Overweight And Obesity ◽  
Hamilton Depression Scale ◽  
Bipolar Patients

IntroductionOverweight and obesity, despite their comorbidities and mortality, could deteriorate the quality of life of people with bipolar disorder.ObjectivesThe objective of this study is to evaluate the quality of life among patients with bipolar disorder and investigate a possible interaction between obesity and deterioration of the quality of life.AimsThis study aims to highlight the importance of preventing overweight and obesity in people with bipolar disorder to obtain an adequate quality of life subsequently an acceptable control of the illness.MethodsFifty euthymic bipolar patients (Hamilton Depression Scale score ≤ 8, and Young Mania Rating Scale score ≤ 6) received the Medical Outcomes Study 36-Item Short-Form Health Survey in Arabic validated version in order to investigate the quality of life.ResultsWe examined 50 euthymic bipolar patients (60% men, 40% women). The average age was 46, 5 years (23–70). Most patients (69%) were over weighted (BMI ≥ 25.0 kg/m2) (body mass index), of whom 40% were obese (BMI ≥ 30.0 kg/m2). Seventy-two percent of the investigated patients had an affected quality of life (score < 66.7). The mental items were deteriorated in 80% of the cases. An affected quality of life was correlated with obesity. The BMI was significantly and negatively correlated with the scores of dimensions D4 (mental health) and D8 (perceived health) (P < 0.01).ConclusionThe investigation of quality of life in people with mental disorder enables to reveal the social handicap caused by these illnesses consequently emphasizes health care in mental affections.Disclosure of interestThe authors have not supplied their declaration of competing interest.

scholarly journals Pre-treatment Depression and Anxiety Disorder in Men with Cancer of the Prostate in South Western Nigeria

2021 ◽  
pp. 46-53
Author(s):  
Adegun Patrick Temi ◽  
Dada Mobolaji Usman ◽  
Idowu Ademola ◽  
Omonisi Abidemi Emmanuel ◽  
Oluwole Lateef Olutoyin ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Anxiety Disorder ◽  
Psychiatric Morbidity ◽  
Depression Scale ◽  
Anxiety And Depression ◽  
Life Questionnaire ◽  
Depression And Anxiety ◽  
Pre Treatment ◽  
Cancer Of The Prostate

Aim: The aim of the study is to determine the pre-treatment prevalence and associated factors of anxiety and depression in men with cancer of the prostate. Study Design: This is a prospective, cross-sectional study. Place and Duration:  The urology unit of Ekiti State University Teaching Hospital, Ado-Ekiti. Ekiti State, Nigeria. The study period was from 1st January 2018 to 31st December 2019. Methodology: A total of 46 consented male participants recently diagnosed with cancer of the prostate (CAP) were assessed for depression and anxiety disorders using the Hospital Anxiety and Depression Scale (HADS). Participants also completed a sociodemographic questionnaire, an 8-item International Prostate Symptoms Score (IPSS) and a quality of life questionnaire (BS). Results: Forty-three and half percent (43.5%) of the participants suffered depression; anxiety disorder occurred in 21.7% of the participants. Only 2.2% of the participants had anxiety disorder without depression, while 23.9% had depression without anxiety disorder. Significant level of poor quality of life (QoL) was found among participants with depression and anxiety disorder. Having one psychiatric morbidity was associated with having another. Age of participants and other sociodemographic parameters were not associated with psychiatric morbidity. Conclusion: There is a high prevalence of anxiety disorder and depression among patients with cancer of the prostate. Assessment of these disorders should be included in the management of patients with prostate cancer to enhance early detection and prompt treatment for better patients’ clinical outcome.

Clinical and Psychological Assessment on Xinwei Decoction for Treating Functional Dyspepsia Accompanied with Depression and Anxiety

2005 ◽  
Vol 33 (02) ◽  
pp. 249-257 ◽  
Author(s):  
Lei Zhao ◽  
Ai-Ping Gan
Keyword(s):  
Herbal Medicine ◽  
Functional Dyspepsia ◽  
Depression Scale ◽  
The Other ◽  
Hamilton Depression Scale ◽  
Depression And Anxiety ◽  
Symptom Scale ◽  
Traditional Chinese Herbal Medicine ◽  
Before And After ◽  
Hamilton Anxiety Scale

The purpose of this study is to explore the psychological efficacy of Xinwei Decoction, a traditional Chinese herbal medicine, to treat functional dyspepsia (FD) accompanied with depression and anxiety. Seventy-three subjects, divided into three groups, had been given herbal medicine (Xinwei Decoction), prokinetic agent (Domperidone) and placebo, respectively for 8 weeks. Before and after treatment, all subjects were examined with FD symptom scale, Hamilton Depression Scale (HAMD) and Hamilton Anxiety Scale (HAMA). As a result, the total scores of the three groups in FD symptom scale, HAMD and HAMA after treatment decreased in different levels, with the decrease in the herbal group more significant than the other two groups ( p <0.01), indicating the efficacy of the herbal medicine. The total effective rates of the herbal, Domperidone and placebo groups were 90%, 67% and 31%, respectively, which indicated significant effect differences between Xinwei Decoction and Domperidone ( p <0.05) and between Xinwei Decoction and placebo ( p <0.01), showing that the efficacy of herbal therapy was superior to that of the other two therapies. Furthermore, there was no one in the Domperidone and placebo groups being cured of depression and anxiety, while the curing rate in the herbal group was about 70%, indicating the efficacy of herbal medicine in comparison to that of Domperidone and placebo for anti-depression and anti-anxiety. The result demonstrated that Xinwei Decoction could not only alleviate FD symptoms but also relieve depression and anxiety.

scholarly journals Antiepileptic, behavioral, and antidepressant effects of adjuvant lamotrigine therapy in drug-resistant epilepsy

2004 ◽  
Vol 61 (5) ◽  
pp. 485-490 ◽  
Author(s):  
Zarko Martinovic ◽  
Nevenka Buder ◽  
Maja Milovanovic ◽  
Ruzica Velickovic
Keyword(s):  
Quality Of Life ◽  
Depression Scale ◽  
Behavioral Effects ◽  
Control Group ◽  
Life Questionnaire ◽  
Hamilton Depression Scale ◽  
Drug Resistant ◽  
Drug Resistant Epilepsy

Aim. To evaluate the behavioral effects of lamotrigine as add-on therapy in treatment-resistant epilepsy. Methods. An open, prospective, long-term study of lamotrigine as adjuvant therapy was performed in 56 patients with drug-resistant epilepsy (female/male ratio 35/21, age range 16-51 years). All the patients kept seizure diaries, and electroencephalograms were recorded at baseline and during 24 months of the treatment. Quality of life questionnaire, Hamilton depression scale (HMD), Beck depression scale (BDI), and Hamilton anxiety scale (HMA) were used before and during lamotrigine therapy. Comparative assessments were made in an age- and sex-matched control group treated with other antiepileptic drugs. Results. Overall, seizure control was improved in 55.3% of the patients, remained unchanged in 39.3%, and deteriorated in 5.4%. Improvement in some quality of life measures occurred in 50% of the patients. The HMD subscales and BDI scale showed significant improvement in lamotrigine treated patients compared to the control group (ANOVA, p < 0.01). Negative behavioral effects occurred in 10.7% of the patients. Conclusion. Lamotrigine demonstrated significant antiepileptic long-term efficacy, and its positive effects on the mood and quality of life, which surpassed the negative behavioral effects, and contributed highly to the favorable treatment outcome.

FRAILTY IS A GERIATRIC SYNDROME CHARACTERIZED BY MULTIPLE IMPAIRMENTS: A COMPREHENSIVE APPROACH IS NEEDED

2016 ◽  
pp. 1-6
Author(s):  
L.-K. CHEN ◽  
A.-C. HWANG ◽  
L.-K. LIU ◽  
W.-J. LEE ◽  
L.-N. PENG
Keyword(s):  
Quality Of Life ◽  
Alcohol Drinking ◽  
Short Form ◽  
Depression Scale ◽  
Community Dwelling ◽  
Geriatric Syndrome ◽  
Life Questionnaire ◽  
Functional Impairments ◽  
Middle Aged

Objective: To evaluate the prevalence of frailty and the associated multimorbidity and functional impairments among community-dwelling middle-aged and elderly people in Taiwan. Design: a cross-sectional study. Setting: communities in I-Lan County of Taiwan. Participants: 1839 community-dwelling people aged 50 years and older. Intervention: None. Measurements: Frailty defined by Fried’s criteria, Charlson’s comorbidity index (CCI), Functional Autonomy Measurement System (SMAF), Center for Epidemiologic Studies Depression Scale (CES-D), Mini-Nutrition Assessment (MNA), Mini–Mental State Examination (MMSE), and Short Form-12 quality of life questionnaire. Results: Overall, 1839 subjects (mean age: 63.9±9.3 years, 47.5% males) participated in this study and men were more likely to have higher educational level, more smoking and alcohol drinking habit. The prevalence of frailty was 6.8% in this study, while pre-frailty was 40.5% and 53.7% of all participants were robust. Compared to subjects with different frailty status, age, education year, alcohol drinking, hypertension, diabetes mellitus, hyperlipidemia, CCI, walking speed, handgrip strength, score of SMAF, CES-D, MNA, MMSE, quality of life were significantly different between groups (P all< 0.05). Older age, poorer physical function, poorer cognitive function, poorer nutritional status, more depressive symptoms, higher CCI and poorer quality of life were all independently associated with frailty. Conclusions: Frailty was not simply a geriatric syndrome, but the combination of multiple geriatric syndromes. Further study is needed to evaluate the clinical benefits of intervention programs for community-dwelling middle-aged and older people to reverse frailty and its associated functional impairments.

scholarly journals Depression and other nonmotor manifestations of Parkinson’s disease

2017 ◽  
Vol 95 (5) ◽  
pp. 419-424
Author(s):  
I. A. Zhukova ◽  
N. G. Zhukova ◽  
V. M. Alifirova ◽  
M. A. Nikitina ◽  
O. P. Izhboldina ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Rating Scale ◽  
Short Form ◽  
Depression Scale ◽  
Severe Depression ◽  
Well Being ◽  
Life Questionnaire

Background. The occurrence of emotional, cognitive, behavioral disorders associated with Parkinson’s disease is on the average 1.5-3 times higher than in the general population of the same age. At least one neuropsychiatric symptom is diagnosed in 77% of the patients and 46% have combination of three or more disturbances. Non-motor disturbances are manifested at all stages of Parkinson’s disease, but information about the relationship between their frequency and manifestations and the duration and severity of the disease is rather contradictory. Aim. To evaluate the prevalence and severity of depression and other non-motor symptoms in patients with Parkinson’s disease. Materials and methods. 206 patients at the average age 65.9±9.7 yr with Parkinson’s disease receiving pharmacotherapy were studied. The clinical assessment was carried out using the Unified Parkinson’s Disease Rating Scale, Hoehn & Yahr Scale, Beck depression inventory II, Hospital anxiety and depression scale, Apathy Scale, Questionnaire for Impulsive-Compulsive Disorders in PD-Rating Scale, Montreal Cognitive Assessment, Parkinson’s Disease Quality of Life Questionnaire- 39, Medical Outcomes Study 36-Item Short Form. Results. 30.9% of the 62 patients with Parkinson’s disease suffered mild, 56 (27.4%) moderate, 21 (10.2%) severe depression and only 67 (32.5%) patients had no depression. The study revealed correlation of depression with apathy (r=0,488; p<0,001), low quality of life according to the PDQ-39 (r=0,471; p<0,001), cognition (r=0,451; p<0,001), emotional well-being (r=0,450; p≤0,001), anxiety (r=0,436; p<0,001). Conclusion. The prevalence of depression in patients with Parkinson’s disease is up to 67.5%. The proportion of patients with severe depression reaches 10.2%. Depression is one of the most frequent non-motor syndromes of Parkinson’s disease deteriorating the quality of life of the patients.

Translation and Validation of the Thai Version of the Wisconsin Quality of Life Questionnaire (TH WISQoL) for Kidney Stone Patients

2020 ◽  
Vol 103 (11) ◽  
pp. 1194-1199
Keyword(s):  
Quality Of Life ◽  
Internal Consistency ◽  
Kidney Stone ◽  
Convergent Validity ◽  
Large Scale ◽  
Short Form ◽  
Outcome Measurement ◽  
Life Questionnaire ◽  
Sf 36

Objective: To develop and validate a Thai version of the Wisconsin Quality of Life (TH WISQoL) Questionnaire. Materials and Methods: The authors developed the TH WISQoL Questionnaire based on a standard multi-step process. Subsequently, the authors recruited patients with kidney stone and requested them to complete the TH WISQoL and a validated Thai version of the 36-Item Short Form Survey (TH SF-36). The authors calculated the internal consistency and interdomain correlation of TH WISQoL and compared the convergent validity between the two instruments. Results: Thirty kidney stone patients completed the TH WISQoL and the TH SF-36. The TH WISQoL showed acceptable internal consistency for all domains (Cronbach’s alpha 0.768 to 0.909). Interdomain correlation was high for most domains (r=0.698 to 0.779), except for the correlation between Vitality and Disease domains, which showed a moderate correlation (r=0.575). For convergent validity, TH WISQoL demonstrated a good overall correlation to TH SF-36, (r=0.796, p<0.05). Conclusion: The TH WISQoL is valid and reliable for evaluating the quality of life of Thai patients with kidney stone. A further large-scale multi-center study is warranted to confirm its applicability in Thailand. Keywords: Quality of life, Kidney stone, Validation, Outcome measurement

scholarly journals Development and validation of a short version of the Sarcopenia Quality of Life questionnaire: the SF-SarQoL

2021 ◽  
Author(s):  
A. Geerinck ◽  
C. Beaudart ◽  
J.-Y. Reginster ◽  
M. Locquet ◽  
C. Monseur ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Short Form ◽  
Reduction Process ◽  
Community Dwelling ◽  
Short Version ◽  
Second Phase ◽  
Life Questionnaire ◽  
Quality Of Life Questionnaire ◽  
Two Phases

Abstract Purpose To facilitate the measurement of quality of life in sarcopenia, we set out to reduce the number of items in the previously validated Sarcopenia Quality of Life (SarQoL®) questionnaire, and to evaluate the clinimetric properties of this new short form. Methods The item reduction process was carried out in two phases. First, information was gathered through item-impact scores from older people (n = 1950), a Delphi method with sarcopenia experts, and previously published clinimetric data. In the second phase, this information was presented to an expert panel that decided which of the items to include in the short form. The newly created SFSarQoL was then administered to older, community-dwelling participants who previously participated in the SarcoPhAge study. We examined discriminative power, internal consistency, construct validity, test–retest reliability, structural validity and examined item parameters with a graded response model (IRT). Results The questionnaire was reduced from 55 to 14 items, a 75% reduction. A total of 214 older, community-dwelling people were recruited for the validation study. The clinimetric evaluation showed that the SF-SarQoL® can discriminate on sarcopenia status [EWGSOP2 criteria; 34.52 (18.59–43.45) vs. 42.86 (26.56–63.69); p = 0.043], is internally consistent (α = 0.915, ω = 0.917) and reliable [ICC = 0.912 (0.847–0.942)]. A unidimensional model was fitted (CFI = 0.978; TLI = 0.975; RMSEA = 0.108, 90% CI 0.094–0.123; SRMR = 0.055) with no misfitting items and good response category separation. Conclusions A new, 14-item, short form version of the Sarcopenia Quality of Life questionnaire has been developed and shows good clinimetric properties.

Sign in / Sign up

Export Citation Format

Share Document